Inactive Instrument

G9pharma co., LTD

Equities

A078650

KR7078650009

Medical Equipment, Supplies & Distribution

Tranche Update on Kolen Co. Ltd.'s Equity Buyback Plan announced on September 22, 2014.

December 15, 2014

From September 22, 2014 to December 15, 2014, the company has repurchased 200,000 shares, representing 2.32% for KRW 751.76 million. With this, the company has completed the repurchase of 200,000 shares, representing 2.32% for KRW 751.76 million under the buyback announced on September 22, 2014.

Latest news about G9pharma co., LTD

G9pharma co., LTD Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
G9pharma co., LTD Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
G9pharma co., LTD Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
G9pharma co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
G9pharma co., LTD Reports Earnings Results for the Full Year Ended December 31, 2022	23/03/23	CI
G9pharma co., LTD Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
G9pharma co., LTD Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	16/08/22	CI
G9pharma co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2022	16/05/22	CI
G9pharma co., LTD Reports Earnings Results for the Full Year Ended December 31, 2021	22/03/22	CI
G9pharma co., LTD cancelled the transaction announced on November 26, 2021	24/02/22	CI
G9pharma co., LTD announced that it has received KRW 9.9999984 billion in funding from Meritz Securities Co., Ltd., Investment Arm, Cypress Partners Co., Ltd.	13/12/21	CI
G9pharma co., LTD announced that it has received KRW 5.999999573 billion in funding from Meritz Securities Co., Ltd., Investment Arm	30/11/21	CI
G9pharma co., LTD announced that it expects to receive KRW 1.5 billion in funding from Cypress Partners Co., Ltd.	25/11/21	CI
G9pharma co., LTD announced that it has received KRW 9.99999775 billion in funding from Meritz Securities Co., Ltd., Investment Arm	23/11/21	CI
G9pharma co., LTD Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	15/11/21	CI
Mosaic Ventures, Luck & Trust Co., Ltd., Han International Co., Ltd., Hannam World and Medi Forum Co.,Ltd. completed the acquisition of 20.9% stake in Kolen Co., Ltd from Biolog Device Co., Ltd..	01/06/21	CI
G9pharma co., LTD announced that it expects to receive KRW 17.99999925 billion in funding from Meritz Securities Co., Ltd., Investment Arm, Cypress Partners Co., Ltd.	19/05/21	CI
Mosaic Ventures, Luck & Trust Co., Ltd., Han International Co., Ltd., Hannam World and Medi Forum Co.,Ltd. signed an agreement to acquire 20.9% stake in Kolen Co., Ltd from Biolog Device Co., Ltd. for KRW 15.5 billion.	09/05/21	CI
G9pharma co., LTD announced that it expects to receive KRW 25.999999573 billion in funding from Meritz Securities Co., Ltd., Investment Arm	21/04/21	CI
1EVOLUTION Marketing Research Inc. cancelled the acquisition of 99.99% stake in KOLEN PHILIPPINES INC from Kolen Co., Ltd.	12/04/21	CI
1EVOLUTION MARKETING RESEARCH INC acquired acquired 99.99% stake in KOLEN PHILIPPINES INC from Kolen Co., Ltd for KRW 14.4 billion.	25/02/21	CI
Kolen Co., Ltd announced that it has received KRW 6 billion in funding from Kiwoom Securities Co., Ltd., Mirae Asset Daewoo Co., Ltd., NH Investment & Securities Co., Ltd.	17/12/20	CI
Kolen Co., Ltd announced that it expects to receive KRW 6 billion in funding from Kiwoom Securities Co., Ltd., Mirae Asset Daewoo Co., Ltd., NH Investment & Securities Co., Ltd.	15/12/20	CI
Biolog Device Co., Ltd. acquired an additional 4.86% stake in Kolen Co., Ltd from Eulryul Ji for KRW 4.5 billion.	05/03/20	CI
Kolen Co., Ltd announced that it has received KRW 8 billion in funding from Mirae Asset Daewoo Co., Ltd., NH Investment & Securities Co., Ltd., Kiwoom Securities Co., Ltd.	02/01/20	CI

Chart G9pharma co., LTD

Duration

Period

More charts

Company Profile

G9Pharma Co Ltd, formerly Kolen Co Ltd, is a Korea-based company principally engaged in the manufacture and sale of aspherical optical lenses. The Company manufactures and sells lenses for camera optics and lenses for application optics. The Company's products are used in cell phone lenses, fingerprint recognition, smart wearable products, among others. In additional, the Company is engaged in the business of supplying vaccines, developing antibody drugs, developing protein products and others.

Sector

Medical Equipment, Supplies & Distribution

Calendar

11/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Glasses, Spectacles & Contact Lenses

	1st Jan change	Capi.
ALCON INC.	+22.39%	43.96B
THE COOPER COMPANIES, INC.	-0.30%	18.78B
AUTEK CHINA INC.	-20.50%	2.22B
WARBY PARKER INC.	+25.60%	2.11B
PEGAVISION CORPORATION	+19.17%	1.13B
MINGYUE OPTICAL LENS CO.,LTD.	-38.32%	716M
UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.	-10.65%	645M
MENICON CO., LTD.	-44.53%	632M
SHANGHAI CONANT OPTICAL CO., LTD.	+57.22%	606M

Glasses, Spectacles & Contact Lenses